BeStock  
Stocks › Biotechnology › DSGN

Design Therapeutics DSGN

US equityMarket cap rank #3474Biotechnology
$11.69 −$0.28 (-2.34%)
Pre-market · Oct 8, 8:20 am ET · After hours $11.69 0.00%
Open$11.82
Prev close$11.97
Day range$11.58 – $12.06
Volume344.5K
Market cap$731.58M
P/E (TTM)–
Dividend yield–

Price chart

Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, or Bollinger Bands for the same 20-day/2-standard-deviation channel used in the Technical signals table.

Technical signals

Trend readStrong downtrend

1 bullish · 6 bearish of 7 signals

IndicatorValueSignalReading
Price vs 20-day average-7.7%BearishTrading below the 20-day average of $12.67
Price vs 50-day average-15.3%BearishTrading below the 50-day average of $13.80
Price vs 200-day average-3.1%BearishTrading below the 200-day average of $12.06
50-day vs 200-day50d above 200dBullishThe 50-day average is above the 200-day average
RSI (14)34.4BearishMomentum leans negative
MACD (12,26,9)-0.57BearishMACD line is below its signal line
Bollinger band position20%BearishInside the 20-day bands

Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.

Levels & volatility

Moving averages

AverageLevelPrice vs. it
20-day SMA$12.67-7.7%
50-day SMA$13.80-15.3%
200-day SMA$12.06-3.1%

Recent price levels

LevelPrice
20-day high$15.14
20-day low$11.58
60-day high$16.12
60-day low$11.37
Upper Bollinger band$14.28
Lower Bollinger band$11.06

The 50-day average is currently 14.4% above the 200-day average — consistent with a “golden cross” (bullish) configuration.

30-day volatility51.2%
Average true range5.62% of price
Max drawdown (1y)-35.6%
Volume (10d vs 90d)0.72x

Discussion

No comments yet — be the first to weigh in on DSGN.

Leave a comment

Scroll to Top